Abstract
Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in the p53 gene occur in almost all human cancers with a frequency of up to 80%. However, it is only 20% in breast cancers, 18% in endometrial cancers and 1.5% in cervical cancers. Estrogen receptor alpha (ERα) plays a pivotal role in hormone-dependent cancer development and the status of ERα is used for designing treatment strategy and for prognosis. A closer look at the cross-talk between p53 and ERα has revealed that their activities are mutually regulated. This review will summarize the current body of knowledge on p53, ERα and ERβ in cancer. Clinical correlations between estrogen receptors and p53 status have also been reported. Thus, this review will discuss the relationship between p53 and ERs at both the molecular and clinical levels.
Keywords: Estrogen receptor, hormone-dependent cancer, p53, transcription factors.
Current Molecular Medicine
Title:The p53-Estrogen Receptor Loop in Cancer
Volume: 13 Issue: 8
Author(s): C. Berger, Y. Qian and X. Chen
Affiliation:
Keywords: Estrogen receptor, hormone-dependent cancer, p53, transcription factors.
Abstract: Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in the p53 gene occur in almost all human cancers with a frequency of up to 80%. However, it is only 20% in breast cancers, 18% in endometrial cancers and 1.5% in cervical cancers. Estrogen receptor alpha (ERα) plays a pivotal role in hormone-dependent cancer development and the status of ERα is used for designing treatment strategy and for prognosis. A closer look at the cross-talk between p53 and ERα has revealed that their activities are mutually regulated. This review will summarize the current body of knowledge on p53, ERα and ERβ in cancer. Clinical correlations between estrogen receptors and p53 status have also been reported. Thus, this review will discuss the relationship between p53 and ERs at both the molecular and clinical levels.
Export Options
About this article
Cite this article as:
Berger C., Qian Y. and Chen X., The p53-Estrogen Receptor Loop in Cancer, Current Molecular Medicine 2013; 13 (8) . https://dx.doi.org/10.2174/15665240113139990065
DOI https://dx.doi.org/10.2174/15665240113139990065 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Current Biomarkers (Discontinued) Antibacterial and Antifungal Screening of Novel α-amino Acid Conjugated Bile Acid Derivatives
Current Bioactive Compounds ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
Anti-Cancer Agents in Medicinal Chemistry Antibody-Based Imaging of HER-2: Moving into the Clinic
Current Molecular Medicine Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Chemistry of Bis-Spiroacetal Systems: Natural Products, Synthesis and Stereochemistry
Current Organic Chemistry Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Thyroid Function and Obesity: From Mechanisms to the Benefits of Levothyroxine in Obese Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances of Metal Binding Protein Lactoferrin as an Anti- Microbial Agent
Current Bioactive Compounds Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Molecular Processes Exploited as Drug Targets for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Therapies for Neurological Disease in the Mucopolysaccharidoses
Current Gene Therapy